Abstract: An expression construct is disclosed which comprises: (i) a DNA sequence which encodes at least one guide RNA (gRNA) operatively linked to a transcriptional regulatory sequence so as to allow expression of the gRNA in a target cell; (ii) a barcode sequence for identification of the at least one gRNA operatively linked to a transcriptional regulatory sequence so as to allow expression of the barcode sequence in the target cell.

Abstract: A method of permeabilizing a cell is disclosed. Kits for permeabilizing cells and analysing RNA contents are also disclosed.

Abstract: Kits and methods for single cell or multiple cell transcriptome analysis are provided. An adapter polynucleotide is disclosed which comprises a double-stranded DNA portion of 15 base pairs and no more than 100 base pairs with a 3?single stranded overhang of at least 3 bases and no more than 10 bases, wherein the double stranded DNA portion is at the 5? end of the polynucleotide and wherein the sequence of the 3?single stranded overhang is selected from the group consisting of SEQ ID NOs: 1-8 and 9, wherein the 5? end of the strand of the double-stranded DNA which is devoid of the 3?single stranded overhang comprises a free phosphate.

Abstract: An expression construct is disclosed which comprises: (i) a DNA sequence which encodes at least one guide RNA (gRNA) operatively linked to a transcriptional regulatory sequence so as to allow expression of the gRNA in a target cell; (ii) a barcode sequence for identification of the at least one gRNA operatively linked to a transcriptional regulatory sequence so as to allow expression of the barcode sequence in the target cell.

Abstract: Kits and methods for single cell or multiple cell transcriptome analysis are provided. An adapter polynucleotide is disclosed which comprises a double-stranded DNA portion of 15 base pairs and no more than 100 base pairs with a 3?single stranded overhang of at least 3 bases and no more than 10 bases, wherein said double stranded DNA portion is at the 5? end of the polynucleotide and wherein the sequence of said 3? single stranded overhang is selected from the group consisting of SEQ ID NOs: 1-8 and 9, wherein the 5? end of the strand of said double-stranded DNA which is devoid of said 3? single stranded overhang comprises a free phosphate.

Abstract: Kits and methods for single cell or multiple cell transcriptome analysis are provided. An adapter polynucleotide is disclosed which comprises a double-stranded DNA portion of 15 base pairs and no more than 100 base pairs with a 3? single stranded overhang of at least 3 bases and no more than 10 bases, wherein said double stranded DNA portion is at the 5? end of the polynucleotide and wherein the sequence of said 3? single stranded overhang is selected from the group consisting of SEQ ID NOs: 1-8 and 9, wherein the 5? end of the strand of said double-stranded DNA which is devoid of said 3? single stranded overhang comprises a free phosphate.

Abstract: The present invention provides IFN?2 mutants and active fragments, analogs, derivatives, and variants thereof, nucleotide molecules encoding same, pharmaceutical compositions containing the same, and methods utilizing the same for treating cancer, infectious diseases, and autoimmune diseases.

Abstract: The present invention provides IFN?2 mutants and active fragments, analogs, derivatives, and variants thereof that have improved specific agonist or antagonist activity as compared to wild-type IFN?2. The present invention further provides pharmaceutical compositions comprising IFN?2 mutants useful for treating or preventing cancer, autoimmune diseases, infectious diseases or disorders associated with increased expression of IFN?2.

Abstract: The present invention provides IFN?2 mutants and active fragments, analogs, derivatives, and variants thereof that have improved specific agonist or antagonist activity as compared to wild-type IFN?2. The present invention further provides pharmaceutical compositions comprising IFN?2 mutants useful for treating or preventing cancer, autoimmune diseases, infectious diseases or disorders associated with increased expression of IFN?2.

Abstract: The present invention provides IFN?2 mutants and active fragments, analogs, derivatives, and variants thereof, nucleotide molecules encoding same, pharmaceutical compositions containing the same, and methods utilizing the same for treating cancer, infectious diseases, and autoimmune diseases.